Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor– positive/human epidermal growth factor receptor 2–negative advanced breast cancer who were treatment na¨ıve or had received up to one line of prior endocrine therapy in the advanced setting.